| 1 | | |
|--------|---|---------------------------------|
| 2 | | |
| 3 | | |
| 4 | UNITED STATES DISTRICT COURT | |
| 5 | THE DISTRICT OF NEVADA | |
| 6 7 | SPECTRUM PHARMACEUTICALS, INC. and UNIVERSITY OF STRATHCLYDE, | Case No.: 2:15-cv-00139-JCM-NJK |
| 8 | Plaintiffs, | ORDER |
| 9 | VS. | |
| 10 | AMNEAL PHARMACEUTICALS LLC | |
| 11 | Defendant. | |
| 12 | WHEREAS, on January 23, 2015, Plaintiffs Spectrum Pharmaceuticals, Inc. and | |
| 13 | University of Strathclyde (collectively, "Plaintiffs") commenced this action against Amneal | |
| 14 | Pharmaceuticals, Inc. ("Amneal"), alleging infringement of U.S. Patent No. 6,500,829 ("the | |
| 15 | '829 patent") under 35 U.S.C. § 271(a), (b), (c), and (e)(2)(A) (ECF No. 1); | |
| 16 | WHEREAS Plaintiffs and Amneal have jointly stipulated to final judgment in this | |
| 17 | action in accordance with the Stipulation for Entry of Final Judgment. | |
| 18 | NOW, THEREFORE, IT IS HEREBY ORDERED AS FOLLOWS: | |
| 19 | Judgment is entered in favor of Amneal that claims 1 and 2 of the '829 patent are | |
| 20 | invalid, and claims 3, 4, and 5-14 of the '829 patent are not infringed by ANDA No. 207547 as | |
| 21 | if fully tried and adjudicated. | |
| 22 | IT IS SO ORDERED: | |
| 23 | INTER CTATES DISTRICT HIDSE | |
| 24 | UNITED STATES DISTRICT JUDGE DATED: June 9, 2016 | |
| 25 | DATED: | |

360402

26

27

28